Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-31T15:46:43.681Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacotherapy for obessive-compulsive disorder

Published online by Cambridge University Press:  06 August 2018

John H. Greist  and
James W. Jefferson
John H. Greist*
Affiliation:
University of Wisconsin Medical School, and Dean Foundation for Health, Research and Education, 8000 Excelsior Drive, Suite 302, Madison, Wl 53717–1914. Fax: (608) 833–8033
James W. Jefferson
Affiliation:
University of Wisconsin Medical School, and Dean Foundation for Health, Research and Education, 8000 Excelsior Drive, Suite 302, Madison, Wl 53717–1914. Fax: (608) 833–8033
*
Correspondence: J. H. Greist, University of Wisconsin Medical School, 8000 Excelsior Drive, Suite 302, Madison, Wl 53717–1914, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

Background Pharmacotherapy for obsessive-compulsive disorder (OCD) was seldom beneficial before clomipramine, a potent selective serotonin reuptake inhibitor (SSRI), became available. Subsequent progress in pharmacotherapy for OCD has increased the possibility of effective treatment for most sufferers.

Method Randomised controlled trials of pharmacotherapy for OCD were reviewed, as well as reports of beneficial pharmacotherapy found in open trials and case reports.

Results SSRIs are well-tolerated by patients with OCD, even in large doses. Prose roto n erg i c augmentation is seldom helpful but antipsychotic augmentations seem beneficial for many OCD patients with comorbid tics.

Conclusions Potent SSRIs are the pharmacotherapy of choice for OCD, with a more limited role reserved for monoamine oxidase inhibitors. If one SSRI is ineffective, others may be beneficial. Non-drug therapies are also important in OCD: behaviour therapy is frequently helpful but infrequently available and neurosurgery is sometimes helpful when all other treatments have failed.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 173 , Issue S35: New perspectives in research and treatment of obsessive-compulsive disorder , August 1998 , pp. 64 - 70
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abramowitz, J. S. (1997) Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. Journal of Consulting and Clinical Psychiatry, 65, 44–52.CrossRefGoogle ScholarPubMed
Altemus, M., Swedo, S. E., Leonard, H. L., et al (1994) Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Archives of General Psychiatry, 51, 794–803.Google Scholar
Baer, L., Rauch, S. L., Ballantine, H. T. Jr., et al (1995) Cingulotomy for intractable obsessive-compulsive disorder: prospective long-term follow-up of 18 patients. Archives of General Psychiatry, 52, 384–392.Google Scholar
Baker, R. W., Bermanzohn, R. C., Wirshing, D. A., et al (1997) Obsessions, compulsions, clozapine, and risperidone. CNS Spectrums, 2, 26–36.Google Scholar
Barr, L. C., Goodman, W. K., Price, L. H., et al (1992) The serotonin hypothesis of obsessive-compulsive disorder: implications of pharmacologic challenge studies. Journal of Clinical Psychiatry, 53 (suppl. 4), 17–28.Google Scholar
Barr, L. C., Goodman, W. K., McDougle, C. J., et al (1994) Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Archives of General Psychiatry, 51, 309–317.Google Scholar
Baxter, L. R., Schwartz, J. M., Bergman, K. S., et al (1992) Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive–compulsive disorder. Archives of General Psychiatry, 49, 681–689.CrossRefGoogle ScholarPubMed
Bean, W. B. (1950a) Osler Aphorisms (#211), p. 101. New York: Henry Shuman.Google Scholar
Bean, W. B. (1950b) Osler Aphorisms (#251), p. 118. New York: Henry Shuman.Google Scholar
Bean, W. B. (1950c) Osler Aphorisms (#217), p. 103. New York: Henry Shuman.Google Scholar
Bean, W. B. (1950d) Osler Aphorisms (#118), p. 253. New York: Henry Shuman.Google Scholar
Bejerot, S. & Humble, M. (1991) citalopram treatment of obsessive-compulsive disorder: a pilot study of antiobsessive efficacy. Biological Psychiatry, 29, 443S.Google Scholar
Bisserbe, J. C., Lane, R. M. & Flament, M. F. (1997) A double-blind comparison of sertraline and clomipramine in out-patients with obsessive-compulsive disorder. European Psychiatry, 12, 82–93.Google Scholar
Cottraux, J., Mollard, E., Bouvard, M., et al (1993) Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow-up. Psychiatry Research, 49, 63–75.Google Scholar
Cox, B. J., Swinson, R. P., Morrison, B., et al (1993) Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a metaanalysis Journal of behavior Therapy and Experimental Psychiatry, 24, 149–153.Google Scholar
DeVeaugh-Geiss, J., Katz, R., Landau, P., et al (1991) Clomipramine in the treatment of patients with obsessive-compulsive disorder: the clomipramine collaborative study group. Archives of General Psychiatry, 48, 730–738.Google Scholar
Dursun, S. M. & Reveley, M. A. (1994) Obsessive-compulsive symptoms and clozapine. British Journal of Psychiatry, 165, 267–268.Google Scholar
Fallon, B. A., Campeas, R., Schneier, F. R., et al (1992) Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 4, 70–75.Google Scholar
Fernandez, C. E. & Lopez-Ibor, J. J. (1967) Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies (in Spanish, English abstract). Actas Luso-Españolas de Neurological Psiquiatría Ciencias Afines, 26, 119–147.Google Scholar
Foa, E. B. & Kozak, M. J. (1996) Psychological treatment for obsessive-compulsive disorder. In Long-Term Treatments of Anxiety Disorders (eds Mavissakalian, M. R. & Prien, R. F.), pp. 285–309. Washington, DC: American Psychiatric Press.Google Scholar
Freeman, C. P. L., Trimble, M. R., Deakin, J. F. W., et al (1994) Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Journal of Clinical Psychiatry, 55, 301–305.Google ScholarPubMed
Ghaemi, S. N., Zarate, C. A., Popli, A. P., et al (1995) Is there a relationship between clozapine and obsessive-compulsive disorder: a retrospective chart review. Comprehensive Psychiatry, 36, 267–270.Google Scholar
Goodman, W. K., Price, L. H., Delgado, P. L., et al (1990) Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Archives of General Psychiatry, 47, 577–585.CrossRefGoogle ScholarPubMed
Goodman, W. K., Price, L. H., Woods, S. W., et al (1991) Pharmacologic challenges in obsessive-compulsive disorder. In The Psychobiology of Obsessive-Compulsive Disorder (eds Zohar, J., Insel, T. & Rasmussen, S.), pp. 162–186. New York: Springer.Google Scholar
Grady, T. A., Pigott, T. A., L'Heureux, F., et al (1993) Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. American Journal of Psychiatry, 150, 819–821.Google Scholar
Greist, J. H. (1989) Computer-administered behavior therapists. International Review of Psychiatry, 1, 267–274.Google Scholar
Greist, J. H., Chouinard, G., Duboff, E. (1995a) Double-blind parallel comparison of three dosages of sertraline and placebo in out-patients with obsessive-compulsive disorder. Archives of General Psychiatry, 52, 289–295.Google Scholar
Greist, J. H., Jefferson, J. W., Kobak, K. A., et al (1995b) Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Archives of General Psychiatry, 52, 53–60.Google Scholar
Greist, J. H., Jenike, M. A., Robinson, D., et al (1995c) Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double-blind, placebo-controlled trial. European Journal of Clinical Research, 7, 195–204.Google Scholar
Greist, J. H., Marks, I. M., Baer, L., et al (1998) Self-treatment for obsessive-compulsive disorder using a manual and a computerized telephone interview: a US-UK study. MD Computing, 15, 149–157.Google Scholar
Hewlett, W. A. (1993) The use of benzodiazepines in obsessive-compulsive disorder and Tourette's syndrome. Psychiatric Annals, 23, 309–316.CrossRefGoogle Scholar
Hewlett, W. A., Vinogradov, S. & Agras, W. S. (1992) Clomipramine, clonazepam, and Clonidine treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 12, 420–430.Google Scholar
Hwang, E. C. & Van Woert, M. H. (1979) Antimyoclonic action of clonazepam: the role of serotonin. European Journal of Pharmacology, 60, 31–40.Google Scholar
Janicak, P. G., Davis, J. M., Preskorn, S. H., et al (1993) Assessment and treatment of other disorders. In Principles and Practice of Psychopharmacotherapy (eds Janicak, P. G., Davis, J. M., Preskorn, S. J., et al), pp. 449–490. Baltimore, MA: Williams & Wilkins.Google Scholar
Jefferson, J. W. & Greist, J. H. (1996) The pharmacotherapy of obsessive-compulsive disorder. Psychiatric Annals, 26, 202–209.Google Scholar
Jenike, M. A. (1982) MAOI for obsessive-compulsive disorder. British Journal of Psychiatry, 140, 549.CrossRefGoogle ScholarPubMed
Jenike, M. A., Baer, L., Minichiello, W. E., et al (1997) Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. American Journal of Psychiatry, 154, 1261–1264.Google ScholarPubMed
Joel, S. W. (1959) Twenty month study of iproniazid therapy. Diseases of the Nervous System, 20, 11–14.Google ScholarPubMed
Kobak, K. A., Greist, J. H., Jefferson, J. W., et al (1998) Behavioral versus pharmacological treatments of obsessive-compulsive disorder: a meta-analysis. Psychopharmacology, 136, 205–216.CrossRefGoogle ScholarPubMed
Kopala, L. & Honer, W. G. (1994) Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. American Journal of Psychiatry, 151, 1714–1715.Google Scholar
Koponen, H., Lepola, H. & Leinonen, E. (1995) Citalopram in the treatment of obsessive-compulsive disorder: a report of two cases. European Psychiatry, 10, 209–210.Google Scholar
Koponen, H., Lepola, H. & Leinonen, E., et al (1997) Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatrica Scandinavia, 96, 343–346.Google Scholar
Koran, L. M., McElroy, S. L., Davidson, J. R. T., et al (1996) Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. Journal of Clinical Psychopharmacology, 16, 121–129.CrossRefGoogle ScholarPubMed
Lazosky, A. J., Ruttan, L. & Stanley, M. A. (1993) A meta-analysis of neuropsychological findings in obsessive compulsive disorder. Journal of Clinical Experimental Neuropsychology, 15, 77.Google Scholar
Leonard, H. L., Swedo, S. E., Rapoport, J. L., et al (1989) Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Archives of General Psychiatry, 46, 1088–1092.Google Scholar
Levkovitch, Y., Kronnenberg, Y. & Gaoni, B. (1995) Can clozapine trigger OCD? Journal of the American Academy of Child and Adolescent Psychiatry, 34, 263.Google Scholar
Liebowitz, M. R., Foa, E. B. & Kozak, M. J. (1995) Interim analysis clarification. Journal of Clinical Psychiatry, 56, 435.Google Scholar
Lopez-Ibor, J. J., Saiz, J., Cottraux, J., et al (1996) Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive-compulsive disorder. European Neuropsychopharmacology, 6, 111–118.Google Scholar
Lucey, J. V., Butcher, G., Clare, A. W., et al (1994) The clinical characteristics of patients with obsessive compulsive disorder: a descriptive study of an Irish sample. Irish Journal of Psychological Medicine, 11, 11–14.Google Scholar
March, J. S., Mulle, K. & Herbel, B. (1994) Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: an open trial of a new protocol-driven treatment package. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 333–341.Google Scholar
Marks, I. M., Stern, R. S., Mawson, D., et al (1980) Clomipramine and exposure for obsessive-compulsive rituals: I. British Journal of Psychiatry, 136, 1–25.Google Scholar
Marks, I. M., Lelliott, P., Basoglu, M., et al (1988) Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. British Journal of Psychiatry, 152, 522–534.CrossRefGoogle ScholarPubMed
McDougle, C. J., Goodman, W. K., Price, L. H., et al (1990) Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. American Journal of Psychiatry, 147, 652–654.Google Scholar
McDougle, C. J., Price, L. H., Goodman, W. K., et al (1991) A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: lack of efficacy. Journal of Clinical Psychopharmacology, 11, 175–184.Google Scholar
McDougle, C. J., Goodman, W. K., Leckman, J. F., et al (1993) Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. American Journal of Psychiatry, 150, 647–649.Google Scholar
McDougle, C. J., Goodman, W. K., Leckman, J. F., et al (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry, 51, 302–308.Google Scholar
McGuire, P. K., Bench, C. J., Frith, C. D., et al (1994) Functional anatomy of obsessive-compulsive phenomena. British Journal of Psychiatry, 164, 459–468.Google Scholar
Mindus, P., Rauch, S. L., Nyman, H., et al (1994) Capsulotomy and cingulotomy as treatments for malignant obsessive compulsive disorder: an update. In Current Insights in Obsessive Compulsive Disorder (eds E. Hollander, J. Zohar, D. Marazziti, et al), pp. 245–276.Google Scholar
Morrison, D., Clark, D., Goldfarb, E., et al (1998) Worsening of obsessive-compulsive symptoms following treatment with olanzepine. American Journal of Psychiatry, 155, 855.Google Scholar
Mundo, E., Bareggi, S. R., Pirola, R., et al (1997) Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. Journal of Clinical Psychopharmacology, 17, 4–10.Google Scholar
Murphy, D. L., Zohar, J. & Benkelfat, C. (1989) Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder. British Journal of Psychiatry 155 (suppl. 8), 15–24.Google Scholar
Orloff, L. M., Battle, M. A., Baer, L., et al (1994) Long-term follow-up of 85 patients with obsessive-compulsive disorder. American Journal of Psychiatry, 151, 441–442.Google ScholarPubMed
O'Sullivan, G., Noshirvani, H., Marks, I., et al (1991) Six-year follow-up after exposure and clomipramine therapy for obsessive-compulsive disorder. Journal of Clinical Psychiatry 52, 150–155.Google Scholar
Pato, M. T., Zohar-Kadouch, R., Zohar, J., et al (1988) Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. American Journal of Psychiatry, 145, 1521–1525.Google Scholar
Pato, M. T., Murphy, D. L. & DeVane, C. L. (1991) Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. Journal of Clinical Psychopharmacology, 11, 224–225.Google Scholar
Piccinelli, M., Pini, S., Bellantuono, C., et al (1995) Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. British Journal of Psychiatry, 166, 424–443.Google Scholar
Pigott, T. A., Pato, M. T., Bernstein, S. E., et al (1990) Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results. Archives of General Psychiatry, 7, 926–932.Google Scholar
Pigott, T. A., Pato, M. T., L'Heureux, F., et al (1991) A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. Journal of Clinical Psychophatmacology, 11, 242–248.Google Scholar
Pigott, T. A., L'Heureux, F., Hill, J. L., et al (1992a) A double-blind study of adjuvant buspirone hydrochloride in clorniparmine-treated patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 12, 11–18.Google Scholar
Pigott, T. A., L'Heureux, F., Rubenstein, C. S., et al (1992b) A controlled trial of clonazepam augmentation in OCD patients treated with clomipramine or fluoxetine. APA Annual Meeting. New Research Abstracts, 82.Google Scholar
Pranzatelli, M. R. (1989) Benzodiazepine induced shaking behavior in the rat: structure-activity and relation to serotonin and benzodiazepine receptors. Experimental Neurology, 104, 241–250.Google Scholar
Prasad, A. (1984) A double-blind study of imipramine versus zimelidine in treatment of obsessive-compulsive neurosis. Pharmacopsychiatry, 1, 61–62.Google Scholar
Rauch, S. L., Jenike, M. A., Alpert, N., et al (1994) Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Archives of General Psychiatry, 51, 62–70.CrossRefGoogle ScholarPubMed
Rasmussen, S., Hackett, E., DuBoff, E., et al (1997) A two-year study of sertraline in the treatment of obsessive-compulsive disorder. International Journal of Clinical Psychopharmacology, 12, 309–316.Google Scholar
Ravizza, L., Barzega, G., Bellino, S., et al (1996) Drug treatment of obsessive-compulsive disorder: long-term trial with clomipramine and selective serotonin reuptake inhibitors. Psychopharmacology Bulletin, 32, 167–173.Google Scholar
Remington, G. & Adams, M. (1994) Risperidone and obsessive-compulsive symptoms. Journal of Clinical Psychopharmacology, 14, 358–359.CrossRefGoogle ScholarPubMed
Saiz Ruiz, J., Lopez-Ibor, J. J. Jr, Cottreaux, J., et al (1992) Double-blind comparison of fluoxetine and clomipramine in obsessive-compulsive disorder. European Neuropsychopharmacology, 2, 204–205.Google Scholar
Stein, D. J., Spadaccini, E. & Hollander, E. (1995) Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. International Clinical Psychopharmacology, 10, 11–18.Google Scholar
Swedo, S. E., Leonard, H. L., Kruesi, M. J. P., et al (1992) Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Archives of General Psychiatry, 49, 29–36.Google Scholar
Szegedi, A., Wetzel, H., Leal, M., et al (1995) Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. Journal of Clinical Psychiatry, 57, 257–264.Google Scholar
Thomsen, P. H. (1997) Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. Journal of Child and Adolescent Psychopharmacology, 7, 157–166.Google Scholar
Tollefson, G. D., Rampey, A. H. Jr, Potvin, J. H., et al (1994) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 51, 559–567.Google Scholar
Toutoungi, M. (1992) Potential effect of enalapril on clomipramine. Human Psychopharmacology, 7, 347–349.Google Scholar
Turner, S. M., Beidel, D. C., Spaulding, S. A., et al (1995) The practice of behavior therapy: a national survey of cost and methods. The Behavior Therapist, 18, 1–4.Google Scholar
Vallejo, J., Olivares, J., Marcos, T., et al (1992) Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. British Journal of Psychiatry, 161, 665–670.CrossRefGoogle ScholarPubMed
Van Balkom, A. J., Van Oppen, P., Vermeulen, A. W. A., et al (1994) A meta-analysis on the treatment of obsessive-compulsive disorder: a comparison of antidepressants, behavior, and cognitive therapy. Clinical Psychology Review, 14, 359–381.Google Scholar
van Renynghe de Voxvrie, G. (1968) Use of anafranil in obsessive neuroses (in French). Acta Neurologica Belgica (Bruxelles), 68, 787–792.Google Scholar
Warneke, L. (1989) Intravenous clomipramine therapy in obsessive-compulsive disorder. Canadian Journal of Psychiatry, 34, 853–859.Google Scholar
Weizman, R., Hermesh, H., Karp, L., et al (1993) The platelet benzodiazepine receptor is unaltered in obsessive-compulsive disorder. Clinical Neuropharmacology (New York), 16, 211–215.Google Scholar
Wheadon, D. E., Bushnell, W. D. & Steiner, M. (1993) A Fixed Dose Comparison of 20, 40, or 60 mg Paroxetine to Placebo in the Treatment of Obsessive Compulsive Disorder. Nashville, TN: Vanderbilt University.Google Scholar
Yaryura-Tobias, J. A., Bebirian, R. J., Neziroglu, F. A., et al (1977) Obsessive-compulsive disorders as a serotonergic defect. Research Communications in Psychology, Psychiatry and Behavior, 2, 279–286.Google Scholar
Zohar, J. & Judge, R. (1996) Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. British Journal of Psychiatry, 169, 468–474.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.